Healius (ASX:HLS) Shares Face Value Trap Fears After Goodwill Hit

Healius walked into these results trading at A$0.42 with flat performance over the past week and modest gains over the past three months. The stock carries a reputation as a deep value healthcare play. Today’s headline is not about a revenue story. It is about a large hit to equity value and rising leverage.

The company booked a sizeable goodwill impairment of A$332m and shifted from net cash of A$57.2m to net debt of A$32.8m. That combination sharpened the focus on the balance sheet and on how much patience investors really have left with this turnaround.

Is Healius now a deep value opportunity or a classic value trap, given an A$0.42 share price, a fresh goodwill hit and rising net debt? Compare that compressed price against our valuation analysis for Healius

FY 2026 Earnings Summary

• Total Revenue (TTM to FY 2026): A$1,373.2m vs. A$1,344.2m in TTM to FY 2025 (up 2.1%)
• Net Income from Continuing Operations (TTM to FY 2026): loss of A$408.9m vs. loss of A$563.0m in TTM to FY 2025 (loss narrowed 27.4%)
• Basic EPS (TTM to FY 2026): loss of A$0.56 per share vs. loss of A$0.78 per share in TTM to FY 2025 (per share loss reduced 27.5%)
• Underlying EBITDA (FY 2026): A$258.6m vs. A$239.1m in FY 2025 (up 8.1%)

Prefer clear visuals instead of another wall of numbers and accounting jargon? Get a full picture of Healius with an at a glance breakdown of its balance sheet strength in the company report for Healius.

Healius Bull Case Hinges On Mix And Margin Milestones

The bullish story on Healius is that higher value testing and tight cost control can steadily repair margins. The FY26 numbers give that claim some concrete support. Pathology EBITDA rose A$15m while pathology revenue moved only modestly. That points to better unit economics rather than just more volume. Genomics grew 16.9% and clinical trial work grew very strongly, which fits the idea that a richer test mix can do more of the heavy lifting.

On the cost side, reported flat labour expense in a year that absorbed Fair Work Commission wage decisions is a key milestone. Management attributes this to regional lab consolidation and digital automation. The T27 program delivered A$24.4m of annualised corporate and support savings and a 24.3% reduction in regional lab FTEs. That shows the margin recovery plan is moving from presentations into the profit and loss statement, even if the overall EBIT level remains modest.

Compare that internal grind on margins with external expectations. See whether analysts think the Healius turnaround is credible or are fading the story in the consensus price target analysis for Healius.

Healius Bear Case: Margin Targets Slip As Debt Rises

The bearish view on Healius is that mix, wages and execution risk will keep margins structurally weaker while leverage creeps up. This result gives that concern some backing. EBIT improved to A$30.2m yet the T27 margin goal is now pushed to around December 2028. That delay is a clear milestone missed for anyone expecting a faster earnings rebuild.

Bears also worry that labour and digital spending will absorb much of the efficiency upside. Labour costs were held flat despite Fair Work Commission decisions, which challenges the idea of uncontrollable wage pressure. However, A$27.1m of restructuring and digital costs, plus the ATO settlement and Lumus true up, contributed to a move from net cash to A$32.8m of net debt. The large A$332m goodwill impairment and deferred tax asset write downs underline balance sheet fragility. Overall, the margin story is slower and messier than hoped.

With Healius now carrying A$32.8m of net debt, a A$332m goodwill hit and restructuring costs still flowing, you need to verify how much balance sheet stress the business can absorb. Analyze the full solvency picture in our financial health analysis of Healius stock.

Take Control Of Your Next Move

If the goodwill impairment, net debt shift and mixed margin signals leave you undecided on Healius, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for a setup that fits your plan. Once you have taken a position, keep your decisions grounded with the Portfolio Command Center that cuts through market noise and highlights only the updates that matter most to your holdings. For longer term context and fresh angles on Healius and other stocks, tap into thousands of investor viewpoints through the Community. This way you can spot potential catalysts or emerging risks earlier and stay ahead of the market instead of reacting late.

Seeking Alternatives Beyond Healius Now

Fresh stock ideas can move from quiet to flying once momentum builds. Scan under the radar for now, before the crowd catches up and pricing shifts. Consider acting early if it suits your strategy.

• Spot income workhorses built for staying power. Then review the hand picked 6 dividend fortresses that can help anchor a portfolio while prices still look reasonable.
• Hunt for companies with real balance sheet muscle. Scan the curated list of solid balance sheet and fundamentals stocks (21 results) before these sturdier stocks are fully caught by the crowd.
• Track potential breakout infrastructure themes. Check the focused 39 power grid technology and infrastructure stocks while these plays remain early and pricing still reflects uncertainty.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com